The role of BMPs in bone anabolism and their potential targets SOST and DKK1

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 153-163

  Kamiya, Nobuhiro ^a  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

Author keywords

BMP; Bone anabolic agent; Bone mass; DKK1; Osteoblast; Osteoclast; SOST Sclerostin; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CARRIER PROTEINS AND BINDING PROTEINS; CHORDIN; DICKKOPF 1 PROTEIN; GREMLIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; NOGGIN; OSTEOGENIC PROTEIN 1; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; SMAD PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANGIOGENESIS; ARTICLE; BONE ANABOLISM; BONE DEVELOPMENT; BONE MASS; BONE MATRIX; BONE METABOLISM; BONE REMODELING; CARTILAGE; CARTILAGE CELL; CELL LINEAGE; CYTOPLASM; DOWN REGULATION; ENDOTHELIUM CELL; FRACTURE HEALING; LIGAND BINDING; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84861726292     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020153     Document Type: Article

References (133)

1. Ryan, P.; Saleh, I.; Stassen, L.F. Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates. Postgrad. Med. J., 2009, 85, 674-677.
2. Cosman, F. Parathyroid hormone treatment for osteoporosis. Curr. Opin. Endocrinol. Diabetes Obes., 2008, 15, 495-501.
3. White, A.P.; Vaccaro, A.R.; Hall, J.A.; Whang, P.G.; Friel, B.C.; McKee, M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop., 2007, 31, 735-741.
4. Gupta, M.C.; Khan, S.N. Application of bone morphogenetic proteins in spinal fusion. Cytokine Growth Factor Rev., 2005, 16, 347-355.
5. Garrison, K.R.; Donell, S.; Ryder, J.; Shemilt, I.; Mugford, M.; Harvey, I.; Song, F. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol. Assess., 2007, 11, 1-168.
6. Urist, M.R. Bone: formation by autoinduction. Science, 1965, 150, 893-899.
7. Sampath, T.K.; Reddi, A.H. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc. Natl. Acad. Sci. USA, 1981, 78, 7599-7603.
8. Wozney, J.M.; Rosen, V.; Celeste, A.J.; Mitsock, L.M.; Whitters, M.J.; Kriz, R.W.; Hewick, R.M.; Wang, E.A. Novel regulators of bone formation: molecular clones and activities. Science, 1988, 242, 1528-1534.
9. Luyten, F.P.; Cunningham, N.S.; Ma, S.; Muthukumaran, N.; Hammonds, R.G.; Nevins, W.B.; Woods, W.I.; Reddi, A.H. Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J. Biol. Chem., 1989, 264, 13377-13380.
10. Wozney, J.M. The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev., 1992, 32, 160-167.
11. Massague, J. Receptors for the TGF-beta family. Cell, 1992, 69, 1067-1070.
12. Wrana, J.L.; Attisano, L.; Wieser, R.; Ventura, F.; Massague, J. Mechanism of activation of the TGF-beta receptor. Nature, 1994, 370, 341-347.
13. Chen, D.; Zhao, M.; Mundy, G.R. Bone morphogenetic proteins. Growth Factors, 2004, 22, 233-241.
14. Shim, J.H.; Greenblatt, M.B.; Xie, M.; Schneider, M.D.; Zou, W.; Zhai, B.; Gygi, S.; Glimcher, L.H. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J., 2009, 28, 2028-2041.
15. Wagner, D.O.; Sieber, C.; Bhushan, R.; Borgermann, J.H.; Graf, D.; Knaus, P. BMPs: from bone to body morphogenetic proteins. Sci. Signal., 2010, 3, mr1.
16. Lavery, K.; Swain, P.; Falb, D.; Alaoui-Ismaili, M.H. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J. Biol. Chem., 2008, 283, 20948-20958.
17. Keller, S.; Nickel, J.; Zhang, J.L.; Sebald, W.; Mueller, T.D. Molecular recognition of BMP-2 and BMP receptor IA. Nat. Struct. Mol. Biol., 2004, 11, 481-488.
18. Hatta, T.; Konishi, H.; Katoh, E.; Natsume, T.; Ueno, N.; Kobayashi, Y.; Yamazaki, T. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Biopolymers, 2000, 55, 399-406.
19. Macias-Silva, M.; Hoodless, P.A.; Tang, S.J.; Buchwald, M.; Wrana, J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J. Biol. Chem., 1998, 273, 25628-25636.
20. Rosen V. BMP and BMP inhibitors in bone. Ann. N Y Acad. Sci., 2006, 1068, 19-25.
21. Gazzerro, E.; Gangji, V.; Canalis, E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J. Clin. Invest., 1998, 102, 2106-2114.
22. Zehentner, B.K.; Dony, C.; Burtscher, H. The transcription factor Sox9 is involved in BMP-2 signaling. J. Bone Miner. Res., 1999, 14, 1734-1741.
23. Lee, M.H.; Javed, A.; Kim, H.J.; Shin, H.I.; Gutierrez, S.; Choi, J.Y.; Rosen, V.; Stein, J.L.; van Wijnen, A.J.; Stein, G.S.; Lian, J.B.; Ryoo, H.M. Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor beta1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J. Cell. Biochem., 1999, 73, 114-125.
24. Pan, Q.; Yu, Y.; Chen, Q.; Li, C.; Wu, H.; Wan, Y.; Ma, J.; Sun, F. Sox9, a key transcription factor of bone morphogenetic protein-2-induced chondrogenesis, is activated through BMP pathway and a CCAAT box in the proximal promoter. J. Cell. Physiol., 2008, 217, 228-241.
25. Denker, A.E.; Haas, A.R.; Nicoll, S.B.; Tuan, R.S. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in highdensity micromass cultures. Differentiation, 1999, 64, 67-76.
26. Katagiri, T.; Yamaguchi, A.; Komaki, M.; Abe, E.; Takahashi, N.; Ikeda, T.; Rosen, V.; Wozney, J.M.; Fujisawa-Sehara, A.; Suda, T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol., 1994, 127, 1755-1766.
27. Shukunami, C.; Ohta, Y.; Sakuda, M.; Hiraki, Y. Sequential progression of the differentiation program by bone morphogenetic protein-2 in chondrogenic cell line ATDC5. Exp. Cell Res., 1998, 241, 1-11.
28. Banerjee, C.; Javed, A.; Choi, J.Y.; Green, J.; Rosen, V.; van Wijnen, A.J.; Stein, J.L.; Lian, J.B.; Stein, G.S. Differential regulation of the two principal Runx2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology, 2001, 142, 4026-4039.
29. Yamaguchi, A.; Ishizuya, T.; Kintou, N.; Wada, Y.; Katagiri, T.; Wozney, J.M.; Rosen, V.; Yoshiki, S. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun., 1996, 220, 366-371.
30. Rountree, R.B.; Schoor, M.; Chen, H.; Marks, M.E.; Harley, V.; Mishina, Y.; Kingsley, D.M. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol., 2004, 2, e355.
31. Yoon, B.S.; Ovchinnikov, D.A.; Yoshii, I.; Mishina, Y.; Behringer, R.R.; Lyons, K.M. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102, 5062-5067.
32. Tsumaki, N.; Nakase, T.; Miyaji, T.; Kakiuchi, M.; Kimura, T.; Ochi, T.; Yoshikawa, H. Bone morphogenetic protein signals are required for cartilage formation and differently regulate joint development during skeletogenesis. J. Bone Miner. Res., 2002, 17, 898-906.
33. Retting, K.N.; Song, B.; Yoon, B.S.; Lyons, K.M. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. Development, 2009, 136, 1093-1104.
34. Bandyopadhyay, A.; Tsuji, K.; Cox, K.; Harfe, B.D.; Rosen, V.; Tabin, C.J. Genetic Analysis of the Roles of BMP2, BMP4, and BMP7 in Limb Patterning and Skeletogenesis. PLoS Genet., 2006, 2, e216.
35. Tsuji, K.; Bandyopadhyay, A.; Harfe, B.D.; Cox, K.; Kakar, S.; Gerstenfeld, L.; Einhorn, T.; Tabin, C.J.; Rosen, V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat. Genet., 2006, 38, 1424-1429.
36. Mishina, Y.; Starbuck, M.W.; Gentile, M.A.; Fukuda, T.; Kasparcova, V.; Seedor, J.G.; Hanks, M.C.; Amling, M.; Pinero, G.J.; Harada, S.; Behringer, R.R. Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J. Biol. Chem., 2004, 279, 27560-27566.
37. Okamoto, M.; Murai, J.; Yoshikawa, H.; Tsumaki, N. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J. Bone Miner. Res., 2006, 21, 1022-1033.
38. Kamiya, N.; Ye, L.; Kobayashi, T.; Mochida, Y.; Yamauchi, M.; Kronenberg, H.M.; Feng, J.Q.; Mishina, Y. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development, 2008, 135, 3801-3811.
39. Kamiya, N.; Ye, L.; Kobayashi, T.; Lucas, D.J.; Mochida, Y.; Yamauchi, M.; Kronenberg, H.M.; Feng, J.Q.; Mishina, Y. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J. Bone Miner. Res., 2008, 23, 2007-2017.
40. Kamiya, N.; Kobayashi, T.; Mochida, Y.; Yu, P.B.; Yamauchi, M.; Kronenberg, H.M.; Mishina, Y. Wnt Inhibitors Dkk1 and Sost are Downstream Targets of BMP Signaling Through the Type IA Receptor (BMPRIA) in Osteoblasts. J. Bone Miner. Res., 2010, 25, 200-210.
41. Zimmerman, L.B.; De Jesus-Escobar, J.M.; Harland, R.M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell, 1996, 86, 599-606.
42. Logan, M.; Martin, J.F.; Nagy, A.; Lobe, C.; Olson, E.N.; Tabin, C.J. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis, 2002, 33, 77-80.
43. Kanczler, J.M.; Oreffo, R.O. Osteogenesis and angiogenesis: the potential for engineering bone. Eur. Cell Mater., 2008, 15, 100-114.
44. Carano, R.A.; Filvaroff, E.H. Angiogenesis and bone repair. Drug Discov. Today, 2003, 8, 980-989.
45. Deckers, M.M.; van Bezooijen, R.L.; van der Horst, G.; Hoogendam, J.; van Der Bent, C.; Papapoulos, S.E.; Lowik, C.W. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology, 2002, 143, 1545-1553.
46. Cheng, H.; Jiang, W.; Phillips, F.M.; Haydon, R.C.; Peng, Y.; Zhou, L.; Luu, H.H.; An, N.; Breyer, B.; Vanichakarn, P.; Szatkowski, J.P.; Park, J.Y.; He, T.C. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J. Bone Joint Surg. Am., 2003, 85-A, 1544-1552.
47. Phillips, F.M.; Bolt, P.M.; He, T.C.; Haydon, R.C. Gene therapy for spinal fusion. Spine J., 2005, 5, 250S-258S.
48. David, L.; Feige, J.J.; Bailly, S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev., 2009, 20, 203-212.
49. Kan, L.; Hu, M.; Gomes, W.A.; Kessler, J.A. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol., 2004, 165, 1107-1115.
50. Lounev, V.Y.; Ramachandran, R.; Wosczyna, M.N.; Yamamoto, M.; Maidment, A.D.; Shore, E.M.; Glaser, D.L.; Goldhamer, D.J.; Kaplan, F.S. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Joint Surg. Am., 2009, 91, 652-663.
51. Yu, P.B.; Deng, D.Y.; Lai, C.S.; Hong, C.C.; Cuny, G.D.; Bouxsein, M.L.; Hong, D.W.; McManus, P.M.; Katagiri, T.; Sachidanandan, C.; Kamiya, N.; Fukuda, T.; Mishina, Y.; Peterson, R.T.; Bloch, K.D. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med., 2008, 14, 1363-1369.
52. Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.S.; Luthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; Colombero, A.; Tan, H.L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T.M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; Tarpley, J.; Derby, P.; Lee, R.; Boyle, W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89, 309-319.
53. Lacey, D.L.; Timms, E.; Tan, H.L.; Kelley, M.J.; Dunstan, C.R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; Hsu, H.; Sullivan, J.; Hawkins, N.; Davy, E.; Capparelli, C.; Eli, A.; Qian, Y.X.; Kaufman, S.; Sarosi, I.; Shalhoub, V.; Senaldi, G.; Guo, J.; Delaney, J.; Boyle, W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93, 165-176.
54. Abe, E.; Yamamoto, M.; Taguchi, Y.; Lecka-Czernik, B.; O'Brien, C.A.; Economides, A.N.; Stahl, N.; Jilka, R.L.; Manolagas, S.C. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J. Bone Miner. Res., 2000, 15, 663-673.
55. Itoh, K.; Udagawa, N.; Katagiri, T.; Iemura, S.; Ueno, N.; Yasuda, H.; Higashio, K.; Quinn, J.M.; Gillespie, M.T.; Martin, T.J.; Suda, T.; Takahashi, N. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology, 2001, 142, 3656-3662.
56. Otsuka, E.; Notoya, M.; Hagiwara, H. Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif. Tissue Int., 2003, 73, 72-77.
57. Paul, S.; Lee, J.C.; Yeh, L.C. A comparative study on BMPinduced osteoclastogenesis and osteoblastogenesis in primary cultures of adult rat bone marrow cells. Growth Factors, 2009, 27, 121-131.
58. Kaneko, H.; Arakawa, T.; Mano, H.; Kaneda, T.; Ogasawara, A.; Nakagawa, M.; Toyama, Y.; Yabe, Y.; Kumegawa, M.; Hakeda, Y. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone, 2000, 27, 479-486.
59. Garimella, R.; Tague, S.E.; Zhang, J.; Belibi, F.; Nahar, N.; Sun, B.H.; Insogna, K.; Wang, J.; Anderson, H.C. Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling. J. Histochem. Cytochem., 2008, 56, 569-577.
60. Laursen, M.; Hoy, K.; Hansen, E.S.; Gelineck, J.; Christensen, F.B.; Bunger, C.E. Recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results. Eur. Spine J., 1999, 8, 485-490.
61. Pradhan, B.B.; Bae, H.W.; Dawson, E.G.; Patel, V.V.; Delamarter, R.B. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976), 2006, 31, E277-E284.
62. Vaidya, R.; Weir, R.; Sethi, A.; Meisterling, S.; Hakeos, W.; Wybo, C.D. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence. J. Bone Joint Surg. Br., 2007, 89, 342-345.
63. Seeherman, H.J.; Li, X.J.; Bouxsein, M.L.; Wozney, J.M. rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J. Bone Joint Surg. Am., 2010, 92, 411-426.
64. Little, D.G.; McDonald, M.; Bransford, R.; Godfrey, C.B.; Amanat, N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J. Bone Miner. Res., 2005, 20, 2044-2052.
65. Harding, A.K.; Aspenberg, P.; Kataoka, M.L.; Bylski, D.; Tagil, M. Manipulating the anabolic and catabolic response in bone graft remodeling: synergism by a combination of local BMP-7 and a single systemic dosis of zoledronate. J. Orthop. Res., 2008, 26, 1245-1249.
66. Chen, W.J.; Jingushi, S.; Hirata, G.; Matsumoto, Y.; Iwamoto, Y. Intramuscular bone induction by the simultaneous administration of recombinant human bone morphogenetic protein 2 and bisphosphonate for autobone graft. Tissue Eng., 2004, 10(11-12), 1652-1661.
67. Harada, S.; Rodan, G.A. Control of osteoblast function and regulation of bone mass. Nature, 2003, 423(6937), 349-355.
68. Hartmann, C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol., 2006, 16(3), 151-158.
69. Krishnan, V.; Bryant, H.U.; Macdougald, O.A. Regulation of bone mass by Wnt signaling. J. Clin. Invest., 2006, 116(5), 1202-1209.
70. Baron, R.; Rawadi, G.; Roman-Roman, S. Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol., 2006, 76, 103-127.
71. Glass, D.A. 2nd; Karsenty, G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr. Top. Dev. Biol., 2006, 73, 43-84.
72. Gong, Y.; Slee, R.B.; Fukai, N.; Rawadi, G.; Roman-Roman, S.; Reginato, A.M.; Wang, H.; Cundy, T.; Glorieux, F.H.; Lev, D.; Zacharin, M.; Oexle, K.; Marcelino, J.; Suwairi, W.; Heeger, S.; Sabatakos, G.; Apte, S.; Adkins, W.N.; Allgrove, J.; Arslan-Kirchner, M.; Batch, J.A.; Beighton, P.; Black, G.C.; Boles, R.G.; Boon, L.M.; Borrone, C.; Brunner, H.G.; Carle, G.F.; Dallapiccola, B.; De Paepe, A.; Floege, B.; Halfhide, M.L.; Hall, B.; Hennekam, R.C.; Hirose, T.; Jans, A.; Juppner, H.; Kim, C.A.; Keppler-Noreuil, K.; Kohlschuetter, A.; LaCombe, D.; Lambert, M.; Lemyre, E.; Letteboer, T.; Peltonen, L.; Ramesar, R.S.; Romanengo, M.; Somer, H.; Steichen-Gersdorf, E.; Steinmann, B.; Sullivan, B.; Superti-Furga, A.; Swoboda, W.; van den Boogaard, M.J.; Van Hul, W.; Vikkula, M.; Votruba, M.; Zabel, B.; Garcia, T.; Baron, R.; Olsen, B.R.; Warman, M.L. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell, 2001, 107(4), 513-523.
73. Mukhopadhyay, M.; Shtrom, S.; Rodriguez-Esteban, C.; Chen, L.; Tsukui, T.; Gomer, L.; Dorward, D.W.; Glinka, A.; Grinberg, A.; Huang, S.P.; Niehrs, C.; Izpisua Belmonte, J.C.; Westphal, H. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev. Cell, 2001, 1(3), 423-434.
74. Li, X.; Liu, P.; Liu, W.; Maye, P.; Zhang, J.; Zhang, Y.; Hurley, M.; Guo, C.; Boskey, A.; Sun, L.; Harris, S.E.; Rowe, D.W.; Ke, H.Z.; Wu, D. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat. Genet., 2005, 37(9), 945-952.
75. Patel, M.S.; Karsenty, G. Regulation of bone formation and vision by LRP5. N. Engl. J. Med., 2002, 346(20), 1572-1574.
76. Ai, M.; Holmen, S.L.; Van Hul, W.; Williams, B.O.; Warman, M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell. Biol., 2005, 25(12), 4946-4955.
77. Li, X.; Zhang, Y.; Kang, H.; Liu, W.; Liu, P.; Zhang, J.; Harris, S. E.; Wu, D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem., 2005, 280(20), 19883-19887.
78. Bodine, P.V.; Zhao, W.; Kharode, Y.P.; Bex, F.J.; Lambert, A.J.; Goad, M.B.; Gaur, T.; Stein, G. S.; Lian, J.B.; Komm, B.S. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol., 2004, 18(5), 1222-1237.
79. Bain, G.; Muller, T.; Wang, X.; Papkoff, J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem. Biophys. Res. Commun., 2003, 301(1), 84-91.
80. Mbalaviele, G.; Sheikh, S.; Stains, J.P.; Salazar, V.S.; Cheng, S.L.; Chen, D.; Civitelli, R. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J. Cell. Biochem., 2005, 94(2), 403-418.
81. Chen, Y.; Whetstone, H.C.; Youn, A.; Nadesan, P.; Chow, E.C.; Lin, A.C.; Alman, B.A. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J. Biol. Chem., 2007, 282(1), 526-533.
82. Winkler, D.G.; Sutherland, M.S.; Ojala, E.; Turcott, E.; Geoghegan, J.C.; Shpektor, D.; Skonier, J.E.; Yu, C.; Latham, J.A. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J. Biol. Chem., 2005, 280(4), 2498-2502.
83. Rawadi, G.; Vayssiere, B.; Dunn, F.; Baron, R.; Roman-Roman, S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J. Bone Miner. Res., 2003, 18(10), 1842-1853.
84. Nakashima, A.; Katagiri, T.; Tamura, M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J. Biol. Chem., 2005, 280(45), 37660-37668.
85. Liu, Z.; Tang, Y.; Qiu, T.; Cao, X.; Clemens, T.L. A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J. Biol. Chem., 2006, 281(25), 17156-17163.
86. Zhang, J.; He, X.C.; Tong, W.G.; Johnson, T.; Wiedemann, L.M.; Mishina, Y.; Feng, J.Q.; Li, L. BMP signaling inhibits hair follicle anagen induction by restricting epithelial stem/progenitor cell activation and expansion. Stem Cells, 2006, 24(12), 2826-2839.
87. Hays, E.; Schmidt, J.; Chandar, N. Beta-catenin is not activated by downregulation of PTEN in osteoblasts. In Vitro Cell Dev. Biol. Anim., 2009, 45(7), 361-370.
88. Huelsken, J.; Vogel, R.; Erdmann, B.; Cotsarelis, G.; Birchmeier, W. beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell, 2001, 105(4), 533-545.
89. Barrow, J.R.; Thomas, K.R.; Boussadia-Zahui, O.; Moore, R.; Kemler, R.; Capecchi, M.R.; McMahon, A.P. Ectodermal Wnt3/beta-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. Genes Dev., 2003, 17(3), 394-409.
90. Kusu, N.; Laurikkala, J.; Imanishi, M.; Usui, H.; Konishi, M.; Miyake, A.; Thesleff, I.; Itoh, N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J. Biol. Chem., 2003, 278(26), 24113-24117.
91. Winkler, D.G.; Sutherland, M.K.; Geoghegan, J.C.; Yu, C.; Hayes, T.; Skonier, J.E.; Shpektor, D.; Jonas, M.; Kovacevich, B.R.; Staehling-Hampton, K.; Appleby, M.; Brunkow, M.E.; Latham, J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J., 2003, 22(23), 6267-6276.
92. Piccolo, S.; Agius, E.; Leyns, L.; Bhattacharyya, S.; Grunz, H.; Bouwmeester, T.; De Robertis, E. M. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature, 1999, 397(6721), 707-710.
93. Bell, E.; Munoz-Sanjuan, I.; Altmann, C.R.; Vonica, A.; Brivanlou, A.H. Cell fate specification and competence by Coco, a maternal BMP, TGFbeta and Wnt inhibitor. Development, 2003, 130(7), 1381-1389.
94. Itasaki, N.; Jones, C.M.; Mercurio, S.; Rowe, A.; Domingos, P.M.; Smith, J.C.; Krumlauf, R. Wise, a context-dependent activator and inhibitor of Wnt signalling. Development, 2003, 130(18), 4295-4305.
95. van Bezooijen, R.L.; Roelen, B.A.; Visser, A.; van der Wee-Pals, L.; de Wilt, E.; Karperien, M.; Hamersma, H.; Papapoulos, S.E.; ten Dijke, P.; Lowik, C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med., 2004, 199(6), 805-814.
96. van Bezooijen, R.L.; Svensson, J.P.; Eefting, D.; Visser, A.; van der Horst, G.; Karperien, M.; Quax, P.H.; Vrieling, H.; Papapoulos, S.E.; ten Dijke, P.; Lowik, C.W. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res., 2007, 22(1), 19-28.
97. Semenov, M.; Tamai, K.; He, X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem., 2005, 280(29), 26770-26775.
98. Morvan, F.; Boulukos, K.; Clement-Lacroix, P.; Roman Roman, S.; Suc-Royer, I.; Vayssiere, B.; Ammann, P.; Martin, P.; Pinho, S.; Pognonec, P.; Mollat, P.; Niehrs, C.; Baron, R.; Rawadi, G. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res., 2006, 21(6), 934-945.
99. Li, J.; Sarosi, I.; Cattley, R.C.; Pretorius, J.; Asuncion, F.; Grisanti, M.; Morony, S.; Adamu, S.; Geng, Z.; Qiu, W.; Kostenuik, P.; Lacey, D.L.; Simonet, W.S.; Bolon, B.; Qian, X.; Shalhoub, V.; Ominsky, M.S.; Zhu Ke, H.; Li, X.; Richards, W.G. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone, 2006, 39(4), 754-766.
100. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J.D. Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med., 2003, 349(26), 2483-2494.
101. Li, X.; Ominsky, M.S.; Niu, Q.T.; Sun, N.; Daugherty, B.; D'Agostin, D.; Kurahara, C.; Gao, Y.; Cao, J.; Gong, J.; Asuncion, F.; Barrero, M.; Warmington, K.; Dwyer, D.; Stolina, M.; Morony, S.; Sarosi, I.; Kostenuik, P.J.; Lacey, D.L.; Simonet, W.S.; Ke, H.Z.; Paszty, C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res., 2008, 23(6), 860-869.
102. Balemans, W.; Ebeling, M.; Patel, N.; Van Hul, E.; Olson, P.; Dioszegi, M.; Lacza, C.; Wuyts, W.; Van Den Ende, J.; Willems, P.; Paes-Alves, A.F.; Hill, S.; Bueno, M.; Ramos, F.J.; Tacconi, P.; Dikkers, F.G.; Stratakis, C.; Lindpaintner, K.; Vickery, B.; Foernzler, D.; Van Hul, W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet., 2001, 10(5), 537-543.
103. Brunkow, M.E.; Gardner, J.C.; Van Ness, J.; Paeper, B.W.; Kovacevich, B.R.; Proll, S.; Skonier, J. E.; Zhao, L.; Sabo, P.J.; Fu, Y.; Alisch, R.S.; Gillett, L.; Colbert, T.; Tacconi, P.; Galas, D.; Hamersma, H.; Beighton, P.; Mulligan, J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet., 2001, 68(3), 577-589.
104. Balemans, W.; Patel, N.; Ebeling, M.; Van Hul, E.; Wuyts, W.; Lacza, C.; Dioszegi, M.; Dikkers, F.G.; Hildering, P.; Willems, P.J.; Verheij, J.B.; Lindpaintner, K.; Vickery, B.; Foernzler, D.; Van Hul, W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet., 2002, 39(2), 91-97.
105. Staehling-Hampton, K.; Proll, S.; Paeper, B.W.; Zhao, L.; Charmley, P.; Brown, A.; Gardner, J. C.; Galas, D.; Schatzman, R.C.; Beighton, P.; Papapoulos, S.; Hamersma, H.; Brunkow, M.E. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet., 2002, 110(2), 144-152.
106. Boyden, L.M.; Mao, J.; Belsky, J.; Mitzner, L.; Farhi, A.; Mitnick, M.A.; Wu, D.; Insogna, K.; Lifton, R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med., 2002, 346(20), 1513-1521.
107. Little, R.D.; Carulli, J.P.; Del Mastro, R.G.; Dupuis, J.; Osborne, M.; Folz, C.; Manning, S.P.; Swain, P.M.; Zhao, S.C.; Eustace, B.; Lappe, M.M.; Spitzer, L.; Zweier, S.; Braunschweiger, K.; Benchekroun, Y.; Hu, X.; Adair, R.; Chee, L.; FitzGerald, M.G.; Tulig, C.; Caruso, A.; Tzellas, N.; Bawa, A.; Franklin, B.; McGuire, S.; Nogues, X.; Gong, G.; Allen, K.M.; Anisowicz, A.; Morales, A.J.; Lomedico, P.T.; Recker, S.M.; Van Eerdewegh, P.; Recker, R.R.; Johnson, M.L. A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bonemass trait. Am. J. Hum. Genet., 2002, 70(1), 11-19.
108. Van Wesenbeeck, L.; Cleiren, E.; Gram, J.; Beals, R.K.; Benichou, O.; Scopelliti, D.; Key, L.; Renton, T.; Bartels, C.; Gong, Y.; Warman, M.L.; De Vernejoul, M.C.; Bollerslev, J.; Van Hul, W. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet., 2003, 72(3), 763-771.
109. Babij, P.; Zhao, W.; Small, C.; Kharode, Y.; Yaworsky, P.J.; Bouxsein, M.L.; Reddy, P.S.; Bodine, P.V.; Robinson, J.A.; Bhat, B.; Marzolf, J.; Moran, R.A.; Bex, F. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res., 2003, 18(6), 960-974.
110. Styrkarsdottir, U.; Halldorsson, B.V.; Gretarsdottir, S.; Gudbjartsson, D.F.; Walters, G.B.; Ingvarsson, T.; Jonsdottir, T.; Saemundsdottir, J.; Snorradottir, S.; Center, J.R.; Nguyen, T.V.; Alexandersen, P.; Gulcher, J.R.; Eisman, J.A.; Christiansen, C.; Sigurdsson, G.; Kong, A.; Thorsteinsdottir, U.; Stefansson, K. New sequence variants associated with bone mineral density. Nat. Genet., 2009, 41(1), 15-17.
111. Huang, Q.Y.; Li, G.H.; Kung, A.W. The-9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone, 2009, 45(2), 289-294.
112. Yerges, L.M.; Klei, L.; Cauley, J.A.; Roeder, K.; Kammerer, C.M.; Moffett, S.P.; Ensrud, K.E.; Nestlerode, C.S.; Marshall, L.M.; Hoffman, A.R.; Lewis, C.; Lang, T.F.; Barrett-Connor, E.; Ferrell, R.E.; Orwoll, E.S.; Zmuda, J.M. High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men. J. Bone Miner. Res., 2009, 24(12), 2039-2049.
113. Issack, P.S.; Lauerman, M.H.; Helfet, D.L.; Doty, S.B.; Lane, J.M. Alendronate Inhibits PTH (1-34)-induced Bone Morphogenetic Protein Expression in MC3T3-E1 Preosteoblastic Cells. HSS J., 2007, 3(2), 169-172.
114. Nakao, Y.; Koike, T.; Ohta, Y.; Manaka, T.; Imai, Y.; Takaoka, K. Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells. Bone, 2009, 44(5), 872-877.
115. Bellido, T. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J. Musculoskelet. Neuronal Interact., 2006, 6(4), 358-359.
116. Leupin, O.; Kramer, I.; Collette, N.M.; Loots, G.G.; Natt, F.; Kneissel, M.; Keller, H. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res., 2007, 22(12), 1957-1967.
117. Huang, J.C.; Sakata, T.; Pfleger, L.L.; Bencsik, M.; Halloran, B.P.; Bikle, D.D.; Nissenson, R.A. PTH differentially regulates expression of RANKL and OPG. J. Bone Miner. Res., 2004, 19(2), 235-244.
118. Glass, D.A. 2nd; Bialek, P.; Ahn, J.D.; Starbuck, M.; Patel, M.S.; Clevers, H.; Taketo, M.M.; Long, F.; McMahon, A.P.; Lang, R.A.; Karsenty, G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell, 2005, 8(5), 751-764.
119. Holmen, S.L.; Zylstra, C.R.; Mukherjee, A.; Sigler, R.E.; Faugere, M.C.; Bouxsein, M.L.; Deng, L.; Clemens, T.L.; Williams, B.O. Essential role of beta-catenin in postnatal bone acquisition. J. Biol. Chem., 2005, 280(22), 21162-21168.
120. Fujita, K.; Janz, S. Attenuation of WNT signaling by DKK-1 and-2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol. Cancer, 2007, 6, 71.
121. Robinson, J.A.; Chatterjee-Kishore, M.; Yaworsky, P.J.; Cullen, D.M.; Zhao, W.; Li, C.; Kharode, Y.; Sauter, L.; Babij, P.; Brown, E.L.; Hill, A.A.; Akhter, M.P.; Johnson, M.L.; Recker, R.R.; Komm, B. S.; Bex, F.J. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J. Biol. Chem., 2006, 281(42), 31720-31728.
122. Robling, A.G.; Niziolek, P.J.; Baldridge, L.A.; Condon, K.W.; Allen, M.R.; Alam, I.; Mantila, S.M.; Gluhak-Heinrich, J.; Bellido, T.M.; Harris, S.E.; Turner, C.H. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem., 2008, 283(9), 5866-5875.
123. Lin, C.; Jiang, X.; Dai, Z.; Guo, X.; Weng, T.; Wang, J.; Li, Y.; Feng, G.; Gao, X.; He, L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res., 2009, 24(10), 1651-1661.
124. Yaccoby, S.; Ling, W.; Zhan, F.; Walker, R.; Barlogie, B.; Shaughnessy, J.D. Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 2007, 109(5), 2106-2111.
125. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S.A.; Shen, Z.; Patel, N.; Tai, Y.T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K.C.; Stover, D.R.; Munshi, N. C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 2009, 114(2), 371-379.
126. Li, X.; Ominsky, M.S.; Warmington, K.S.; Morony, S.; Gong, J.; Cao, J.; Gao, Y.; Shalhoub, V.; Tipton, B.; Haldankar, R.; Chen, Q.; Winters, A.; Boone, T.; Geng, Z.; Niu, Q.T.; Ke, H.Z.; Kostenuik, P.J.; Simonet, W.S.; Lacey, D.L.; Paszty, C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res., 2009, 24(4), 578-588.
127. Styrkarsdottir, U.; Cazier, J.B.; Kong, A.; Rolfsson, O.; Larsen, H.; Bjarnadottir, E.; Johannsdottir, V.D.; Sigurdardottir, M.S.; Bagger, Y.; Christiansen, C.; Reynisdottir, I.; Grant, S.F.; Jonasson, K.; Frigge, M.L.; Gulcher, J.R.; Sigurdsson, G.; Stefansson, K. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol., 2003, 1(3), E69.
128. Reneland, R.H.; Mah, S.; Kammerer, S.; Hoyal, C.R.; Marnellos, G.; Wilson, S.G.; Sambrook, P. N.; Spector, T.D.; Nelson, M.R.; Braun, A. Association between a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Med. Genet., 2005, 6, 9.
129. Canalis, E. Growth factor control of bone mass. J. Cell. Biochem., 2009, 108(4), 769-777.
130. Gazzerro, E.; Canalis, E. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord., 2006, 7(1-2), 51-65.
131. Yu, Y.Y.; Lieu, S.; Lu, C.; Miclau, T.; Marcucio, R.S.; Colnot, C. Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair. Bone, 2010, 46(3), 841-851.
132. Morgan, E.F.; Mason, Z.D.; Bishop, G.; Davis, A.D.; Wigner, N.A.; Gerstenfeld, L.C.; Einhorn, T. A. Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone, 2008, 43(6), 1031-1038.
133. Tay, B.K.; Le, A.X.; Gould, S.E.; Helms, J.A. Histochemical and molecular analyses of distraction osteogenesis in a mouse model. J. Orthop. Res., 1998, 16(5), 636-642.